Thus, considering the immunogenic role of ENO1 as a tumour associated antigen, coupled with its overexpression in PDAC as a plasminogen receptor at the cell surface, the targeting of PDAC cancer cells with anti-ENO1 antibodies may represent an attractive immunotherapeutic approach for inhibiting tumour metastasis [163]. The gene discussed is ENO1; the disease is neoplasm.